APA (7th ed.) Citation

Donk, N. W. C. J. v. d., Bahlis, N., Costa, L. J., Mateos, M., Nooka, A. K., Perrot, A., . . . Usmani, S. Z. (2024, October). Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study. Blood Cancer Journal.

Chicago Style (17th ed.) Citation

Donk, Niels W. C. J. van de, et al. "Impact of COVID-19 on Outcomes with Teclistamab in Patients with Relapsed/refractory Multiple Myeloma in the Phase 1/2 MajesTEC-1 Study." Blood Cancer Journal Oct. 2024.

MLA (9th ed.) Citation

Donk, Niels W. C. J. van de, et al. "Impact of COVID-19 on Outcomes with Teclistamab in Patients with Relapsed/refractory Multiple Myeloma in the Phase 1/2 MajesTEC-1 Study." Blood Cancer Journal, Oct. 2024.